Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $65.00 at Oppenheimer

Tarsus Pharmaceuticals (NASDAQ:TARS) had its target price lifted by research analysts at Oppenheimer from $63.00 to $65.00 in a research report issued on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target points to a potential upside of 44.99% from the company’s current price.

Separately, William Blair raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $54.20.

Tarsus Pharmaceuticals Trading Down 3.9 %

Shares of TARS opened at $44.83 on Thursday. The stock’s fifty day simple moving average is $37.84 and its 200-day simple moving average is $32.52. The firm has a market capitalization of $1.71 billion, a PE ratio of -11.77 and a beta of 1.00. Tarsus Pharmaceuticals has a 12-month low of $15.60 and a 12-month high of $52.99. The company has a quick ratio of 6.99, a current ratio of 7.03 and a debt-to-equity ratio of 0.28.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Cowen AND Company LLC increased its position in shares of Tarsus Pharmaceuticals by 3.5% in the 2nd quarter. Cowen AND Company LLC now owns 2,197,385 shares of the company’s stock valued at $59,725,000 after buying an additional 74,855 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of Tarsus Pharmaceuticals by 47.2% in the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock worth $71,653,000 after acquiring an additional 698,712 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Tarsus Pharmaceuticals by 14.5% during the first quarter. Vanguard Group Inc. now owns 1,826,632 shares of the company’s stock worth $66,398,000 after purchasing an additional 231,131 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Tarsus Pharmaceuticals by 7.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock valued at $37,536,000 after purchasing an additional 77,825 shares in the last quarter. Finally, Ikarian Capital LLC grew its position in shares of Tarsus Pharmaceuticals by 28.7% in the 3rd quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock valued at $33,886,000 after purchasing an additional 230,000 shares during the period. 90.01% of the stock is currently owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.